FULL ESTIMATED COST 0.15 0.15

FILE 'MEDLINE' ENTERED AT 13:58:09 ON 11 MAY 2001

FILE LAST UPDATED: 2 MAY 2001 (20010502/UP). FILE COVERS 1958 TO DATE.

On April 22, 2001, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE now contains new records from the former NLM HEALTH STAR database. These records have an Entry Date and Update Date of 20010223.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2001 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

```
=> e female sexual dysfunction/ct
E#   FREQUENCY    AT     TERM
--   ---------    --     ----
E1           0     2     FEMALE INHIBIN/CT
E2           0     1     FEMALE SEQUENTIAL/CT
E3           0       --> FEMALE SEXUAL DYSFUNCTION/CT
E4           0     2     FEMALE STERILITY/CT
E5           0     2     FEMALE STERILIZATION/CT
E6           0     2     FEMALE STERILIZATION, VOLUNTARY/CT
E7           0     2     FEMALE STERILIZATIONS/CT
E8           0     2     FEMALE STERILIZATIONS, VOLUNTARY/CT
E9           0     2     FEMALES/CT
E10        352    56     FEMINISM/CT
E11         33            FEMINISM: HI, HISTORY/CT
E12          0     1     FEMINIST/CT
```

```
=> fil caplus
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY     SESSION
FULL ESTIMATED COST                            0.30        0.45
```

FILE 'CAPLUS' ENTERED AT 13:58:36 ON 11 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 11 May 2001 VOL 134 ISS 21
FILE LAST UPDATED: 10 May 2001 (20010510/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
=> e female sexual dysfunction/ct
E#    FREQUENCY     AT      TERM
--    ---------     --      ----
E13           0      2      FEMALE REPRODUCTIVE TRACT TUMOR/CT
E14           0      2      FEMALE SEX ORGAN/CT
E15           0        --> FEMALE SEXUAL DYSFUNCTION/CT
E16           0      2      FEMALE STERILITY/CT
E17          40      2      FEMALE STERILITY (ANIMAL)/CT
E18           0      2      FEMALE, CYCLE REPRODUCTION/CT
E19           0      2      FEMALE, DISEASE REPRODUCTIVE TRACT/CT
E20           0      2      FEMALE, DISORDER FERTILITY/CT
E21           0      2      FEMALE, DISORDER, PRECOCIOUS PUBERTY/CT
E22           1             FEMENIASIA/CT
E23           0      1      FEMINIZATION/CT
E24           0      2      FEMINIZATION TESTIS/CT
```

```
=> e female sexual dysfunction
E25           2      FEMAL2/BI
E26      103444      FEMALE/BI
E27           0 --> FEMALE SEXUAL DYSFUNCTION/BI
E28           1      FEMALE1/BI
E29           1      FEMALEA/BI
E30           1      FEMALEAND/BI
E31           3      FEMALED/BI
E32           1      FEMALELETHAL2D/BI
E33           2      FEMALELIKE/BI
E34          82      FEMALENESS/BI
E35           1      FEMALERECIPIENTS/BI
E36       47247      FEMALES/BI
```

```
=> fil medline caplus embase biosis uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.33       0.78

FILE 'MEDLINE' ENTERED AT 13:59:28 ON 11 MAY 2001

FILE 'CAPLUS' ENTERED AT 13:59:28 ON 11 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:59:28 ON 11 MAY 2001
```

FILE 'BIOSIS' ENTERED AT 13:59:28 ON 11 MAY 2001

FILE 'USPATFULL' ENTERED AT 13:59:28 ON 11 MAY 2001


```
=> s misoprotol
L1          42 MISOPROTOL

=> s misoprostol
L2        7197 MISOPROSTOL

=> s female (s) (sexual? dysfunct?)
L3        1063 FEMALE (S) (SEXUAL? DYSFUNCT?)

=> s l2 and l3
L4           4 L2 AND L3

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5           4 DUP REM L4 (0 DUPLICATES REMOVED)

=> d ibib abs

L5   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2001 ACS
ACCESSION NUMBER:         2000:133522  CAPLUS
DOCUMENT NUMBER:          132:185425
TITLE:                    Use of misoprostol or/and
                          misoprostol acid for preparing drug in order
                          to cure sexual dysfunction in women
INVENTOR(S):              Karouzakis, Petros; Kanakaris, Panagiotis
PATENT ASSIGNEE(S):       Greece
SOURCE:                   PCT Int. Appl., 13 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE          APPLICATION NO.  DATE
     ----------------    ----  --------      ---------------  --------
     WO 2000009134       A1    20000224      WO 1999-GR30     19990813
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9951862          A1    20000306      AU 1999-51862    19990813
PRIORITY APPLN. INFO.:                      GR 1998-100315   A  19980814
                                            WO 1999-GR30     W  19990813
```

AB **Misoprostol** or/and **misoprostol** acid are used for prepg. a pharmaceutical in order to cure sexual dysfunction in women. **Misoprostol** or/and **misoprostol** acid are applied externally to the clitoris or/and to the vagina, are absorbed and cause topical vasodilation resulting in the feeling of sexual desire in women

suffering from sexual dysfunction, due to vascular or other causes. Simultaneously **misoprostol** promotes the coming of orgasm.

REFERENCE COUNT: 5
REFERENCE(S):
(1) Carbonell; EUR J CONTRACEPT REPROD HEALTH CARE 1998, V3(2) CAPLUS
(2) Carbonell; vaginal misoprostol for early second-trimester abortion 1998
(3) Centre National de La Recherche Scientifique; FR 960459457 1996
(4) Mundle; OBSTETRICS AND GYNECOLOGY 1996, V88(4), P521 CAPLUS
(5) Mundle; vaginal misoprostol for induction of labor

=> d ibib abs 2-4

L5 ANSWER 2 OF 4 USPATFULL
ACCESSION NUMBER: 1999:110350 USPATFULL
TITLE: Compositions
INVENTOR(S): Dias Nahoum, Cesar Roberto, P.O. Box 1539, King of Prussia, PA, United States 19406-0939

	NUMBER	DATE
PATENT INFORMATION:	US 5952361	19990914
APPLICATION INFO.:	US 1998-37097	19980309 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-444130, filed on 18 May 1995, now patented, Pat. No. US 5773457 which is a continuation of Ser. No. US 1995-381945, filed on 15 Feb 1995	
PRIORITY INFORMATION:	BR 1992-3277	19920821

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Dinner, Dara L.; Venetianer, Stephen; Kinzig, Charles M.
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 4 USPATFULL
ACCESSION NUMBER: 1999:63326 USPATFULL
TITLE: Compositions
INVENTOR(S): Nahoum, Cesar Roberto Dias, SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
PATENT ASSIGNEE(S): Nahoum, Cesar Roberto Dias, Rio de Janeiro, Brazil (non-U.S. individual)

	NUMBER	DATE	
PATENT INFORMATION:	US 5908853	19990601	
	WO 9404120	19940303	
APPLICATION INFO.:	US 1995-381945	19950215	(8)
	WO 1993-BR27	19930818	
		19950215	PCT 371 date
		19950215	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	BR 1992-3277	19920821

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Harrison, Robert H.
LEGAL REPRESENTATIVE: Dinner, Dara L.; Venetianer, Stephen
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction** in an animal, including humans. The H.sub.2 and H.sub.3 agonists may be administered by intracavernousm injection, topically, transdermally, or intraurethrally. The method of use may also include a second therapeutic agent which either facilitates, potentiates or is erectogenic. The second agent may be administered sequentially or contemporaneously with either the H.sub.2 or H.sub.3 agonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 4 USPATFULL
ACCESSION NUMBER: 1998:75603 USPATFULL
TITLE: Compositions
INVENTOR(S): Nahoum, Cesar Roberto Dias, SmithKline Beechman Corporation Corporate Intellectual Property, UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
PATENT ASSIGNEE(S): Nahoum, Cesar Roberto Dias, Rio de Janeiro, Brazil (non-U.S. individual)

	NUMBER	DATE	
PATENT INFORMATION:	US 5773457	19980630	
APPLICATION INFO.:	US 1995-444130	19950518	(8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-381945, filed on 15 Feb 1995
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Dinner, Dara L.; Venetianer, Stephen; Lentz, Edward T.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.11	18.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.59	-0.59

FILE 'STNGUIDE' ENTERED AT 14:02:23 ON 11 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 4, 2001 (20010504/UP).

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.00	18.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.59

FILE 'CAPLUS' ENTERED AT 14:04:47 ON 11 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 11 May 2001 VOL 134 ISS 21
FILE LAST UPDATED: 10 May 2001 (20010510/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in

searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
=> s female (a) (sexual? (a) (dysfunct? or behav? or disord? ))
        103444 FEMALE
         47247 FEMALES
        130419 FEMALE
                 (FEMALE OR FEMALES)
         24427 SEXUAL?
         25407 DYSFUNCT?
        789341 BEHAV?
        284301 DISORD?
L6         464 FEMALE (A) (SEXUAL? (A) (DYSFUNCT? OR BEHAV? OR DISORD? ))

=> s l6 and l2
L7           1 L6 AND L2

=> d ti

L7   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2001 ACS
TI   Use of misoprostol or/and misoprostol acid for
     preparing drug in order to cure sexual dysfunction in women


=> s prostaglandin?
L8       65595 PROSTAGLANDIN?

=> s l8 and l2
L9         441 L8 AND L2

=> s l8 (s) l2
L10        267 L8 (S) L2

=> s l8 (a) l2
L11         43 L8 (A) L2

=> s l11 range=, 1998
L12         30 L8 (A) L2

=> s l11 range=, 1997
L13         24 L8 (A) L2

=> d ti so tot

L13  ANSWER 1 OF 24  CAPLUS  COPYRIGHT 2001 ACS
TI   A comparison of intermittent vaginal administration of misoprostol with
     continuous dinoprostone for cervical ripening and labor induction
SO   Am. J. Obstet. Gynecol. (1997), 177(3), 612-618
     CODEN: AJOGAH; ISSN: 0002-9378

L13  ANSWER 2 OF 24  CAPLUS  COPYRIGHT 2001 ACS
TI   Oral administration of misoprostol for labor induction: a randomized
     controlled trial
SO   Obstet. Gynecol. (N. Y.) (1997), 89(3), 392-397
     CODEN: OBGNAS; ISSN: 0029-7844

L13  ANSWER 3 OF 24  CAPLUS  COPYRIGHT 2001 ACS
TI   Substitution of charged amino acid residues in transmembrane regions 6
and
     7 affect ligand binding and signal transduction of the prostaglandin EP3
```

receptor
SO Mol. Pharmacol. (1997), 51(1), 61-68
CODEN: MOPMA3; ISSN: 0026-895X

L13 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Prevention of post-transplant peptic ulcer by misoprostol
SO Nephron (1996), 74(1), 131-135
CODEN: NPRNAY; ISSN: 0028-2766

L13 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Effects of misoprostol and prostaglandin E2 on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants
SO Prostaglandins (1996), 52(3), 157-173
CODEN: PRGLBA; ISSN: 0090-6980

L13 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation
and differentiation of mouse B lymphocytes to IgE-secreting cells
SO Proc. Natl. Acad. Sci. U. S. A. (1996), 93(20), 10978-10983
CODEN: PNASA6; ISSN: 0027-8424

L13 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Involvement of prostaglandins in the down-regulation of allergic plasma leakage observed in rats undergoing pleural eosinophilia
SO Br. J. Pharmacol. (1996), 118(8), 2192-2198
CODEN: BJPCBM; ISSN: 0007-1188

L13 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the **prostaglandin misoprostol**
SO Br. J. Obstet. Gynaecol. (1996), 103(7), 706-709
CODEN: BJOGAS; ISSN: 0306-5456

L13 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Protective prostaglandins for use in conjunction with chemotherapeutic agents
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2

L13 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Prostaglandin E derivatives in the treatment of dementia
SO Can. Pat. Appl., 12 pp.
CODEN: CPXXEB

L13 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Use of **misoprostol** (**prostaglandin** E1 methyl analog) to expedite delivery in severe preeclampsia remote from term
SO J. Matern.-Fetal Med. (1996), 5(1), 39-40
CODEN: JMFMEC; ISSN: 1057-0802

L13 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain
SO J. Biol. Chem. (1995), 270(27), 16122-7
CODEN: JBCHA3; ISSN: 0021-9258

L13 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI The prostaglandin E1 analog, misoprostol, a normal tissue protector, does not protect four murine tumors in vivo from radiation injury

SO Radiat. Res. (1995), 142(3), 281-7
CODEN: RAREAE; ISSN: 0033-7587

L13 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Effects of prostaglandin E1 analog, misoprostol, on the development of adjuvant arthritis in rats
SO Inflammopharmacology (1995), 3(1), 49-63
CODEN: IAOAES; ISSN: 0925-4692

L13 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI The combined use of prostaglandin and antiprogestin in human fertility control
SO Adv. Prostaglandin, Thromboxane, Leukotriene Res. (1995), 23(Prostaglandins and Related Compounds), 55-62
CODEN: ATLRD6; ISSN: 0732-8141

L13 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI the reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs can be reversed by prostaglandin E1 analog
SO J. Rheumatol. (1994), 21(9), 1748-52
CODEN: JRHUA9; ISSN: 0315-162X

L13 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Comparison of the prostaglandin E (EP) receptor of human neutrophils and HL-60 cells differentiated with DMSO
SO Prostaglandins (1994), 48(4), 221-34
CODEN: PRGLBA; ISSN: 0090-6980

L13 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Misoprostol protection against acetaminophen-induced hepatotoxicity in the rat
SO Dig. Dis. Sci. (1994), 39(6), 1249-56
CODEN: DDSCDJ; ISSN: 0163-2116

L13 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI SC-46275: a potent and highly selective agonist at the EP3 receptor
SO Prostaglandins, Leukotrienes Essent. Fatty Acids (1993), 49(6), 939-43
CODEN: PLEAEU; ISSN: 0952-3278

L13 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Catalytic functionalization of polymers: a novel approach to site-specific delivery of misoprostol to the stomach
SO J. Med. Chem. (1993), 36(21), 3087-97
CODEN: JMCMAR; ISSN: 0022-2623

L13 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Conditional pharmacology: expression of antiinflammatory activity may require pre-existent inflammatory mediators and/or hormones
SO Inflammopharmacology (1991), 1(1), 61-8
CODEN: IAOAES

L13 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets
SO Br. J. Pharmacol. (1988), 94(2), 591-601
CODEN: BJPCBM; ISSN: 0007-1188

L13 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2001 ACS

TI In situ cuprate formation via transmetalation between vinylstannanes and higher order cyanocuprates
SO J. Am. Chem. Soc. (1988), 110(8), 2641-3
CODEN: JACSAT; ISSN: 0002-7863

L13 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2001 ACS
TI Antiulcer **prostaglandin misoprostol**: single and multiple dose pharmacokinetic profile
SO Prostaglandins (1987), 33(Suppl.), 40-50
CODEN: PRGLBA; ISSN: 0090-6980

=> d scan

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-9 (Mammalian Hormones)
TI The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets
ST prostaglandin receptor subtype smooth muscle; blood platelet prostaglandin receptor subtype; **misoprostol prostaglandin** receptor subtype; fenprostalene prostaglandin receptor subtype
IT Blood platelet
(aggregation of, prostaglandin receptor subtypes mediation of, characterization of)
IT Prostaglandins
RL: BIOL (Biological study)
(blood platelet aggregation and smooth muscle contraction response to)
IT Receptors
RL: PROC (Process)
(for prostaglandins, of blood platelets and smooth muscle, characterization of)
IT Trachea (anatomical)
(prostaglandin receptor subtypes of, characterization of)
IT Artery, composition
(aorta, prostaglandin receptor subtypes of, characterization of)
IT Intestine, composition
(colon, prostaglandin receptor subtypes of, characterization of)
IT Intestine, composition
(ileum, prostaglandin receptor subtypes of, characterization of)
IT Esophagus
(muscularis mucosa, prostaglandin receptor subtypes of, characterization of)
IT Vein
(portal, prostaglandin receptor subtypes of, characterization of)
IT Muscle, composition
(smooth, prostaglandin receptor subtypes of, characterization of)
IT 363-24-6, PGE2 551-11-1, PGF2.alpha. 745-65-3, PGE1 35121-78-9, PGI2
39746-25-3, 16,16-Dimethyl PGE2 41598-07-6, PGD2 56985-40-1, U 46619
RL: BIOL (Biological study)
(blood platelet aggregation and smooth muscle contraction response to)
IT 59122-46-2, Misoprostol 69381-94-8, Fenprostalene
RL: BIOL (Biological study)
(blood platelet aggregation and smooth muscle contraction response to, receptors mediation of)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 1-7 (Pharmacology)

TI Conditional pharmacology: expression of antiinflammatory activity may require pre-existent inflammatory mediators and/or hormones
ST antiinflammatory agent edema endogenous inflammation mediator; nonsteroidal inflammation inhibitors antiedema **prostaglandin misoprostol**
IT Prostaglandins
RL: BIOL (Biological study)
(in misoprostol effect on inhibition of edema by antiinflammatory drugs
in normal animals)
IT Edema
(inhibition of, by antiinflammatory drugs, requirement of endogenous inflammatory mediators in)
IT Inflammation
(mediators, endogenous, requirement of, in inhibition of edema by antiinflammatory drugs)
IT Inflammation inhibitors
(nonsteroidal, inhibition of edema by, requirement of endogenous inflammatory mediators in)
IT 59122-46-2, Misoprostol
RL: BIOL (Biological study)
(inhibition of edema by antiinflammatory drugs in normal animals response to, prostaglandins role in)
IT 50-78-2, Aspirin 58-15-1, Aminopyrine 69-72-7, biological studies 69-72-7D, derivs. 99-96-7, 4-Hydroxybenzoic acid, biological studies 119-36-8, Methyl salicylate 142-71-2 2438-72-4 13539-59-8, Azapropazone
RL: BIOL (Biological study)
(inhibition of edema by, requirement of endogenous inflammatory mediators in)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 2, 26
TI Catalytic functionalization of polymers: a novel approach to site-specific
delivery of misoprostol to the stomach
ST polybutadiene misoprostol delivery stomach
IT Stomach
(misoprostol site-specific delivery to, functionalized polybutadiene for)
IT Ulcer inhibitors
(misoprostol, site-specific delivery to stomach of, functionalized polybutadiene for)
IT Hydrolysis
Kinetics of hydrolysis
(of misoprostol reaction products with functionalized polybutadiene)
IT Drug bioavailability
Solution rate
(of misoprostol, from functionalized polybutadiene)
IT Polymer degradation
(hydrolytic, of misoprostol reaction products with functionalized polybutadiene)
IT 14694-95-2, Chlorotris(triphenylphosphine)rhodium
RL: BIOL (Biological study)
(in prepn. of chlorodiisopropylsilylated polybutadiene amine deriv.)
IT 150462-27-4P 150462-28-5P 150462-29-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with functionalized polybutadiene)
IT 994-30-9DP, Triethylchlorosilane, reaction products with polybutadiene and

misoprostol 1066-35-9DP, reaction products with polybutadiene and misoprostol 1609-19-4DP, Diethylchlorosilane, reaction products with polybutadiene and misoprostol 1631-82-9DP, Methylphenylchlorosilane, reaction products with polybutadiene and misoprostol 9003-17-2DP, Polybutadiene, functionalized, reaction products with misoprostol 18162-84-0DP, Octyldimethylchlorosilane, reaction products with polybutadiene and misoprostol 59122-46-2DP, Misoprostol, reaction products with functionalized polybutadiene 150462-26-3DP, reaction products with polybutadiene and misoprostol
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for site specific delivery to stomach)
IT 59122-46-2, Misoprostol
RL: BIOL (Biological study)
(site-specific delivery of, to stomach, functionalized polybutadiene in)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-9 (Mammalian Hormones)
TI SC-46275: a potent and highly selective agonist at the EP3 receptor
ST SC 46275 EP3 receptor agonist
IT Vas deferens
(prostaglandin EP3 receptor of, SC-46275 as agonist for)
IT Prostaglandins
RL: BIOL (Biological study)
(EP3 receptors, SC-46275 as agonist for)
IT Intestine, composition
(ileum, prostaglandin receptors of, agonists for)
IT Receptors
RL: BIOL (Biological study)
(prostaglandin EP3, SC-46275 as agonist for)
IT 137255-19-7, SC-46275
RL: BIOL (Biological study)
(as prostaglandin EP3 receptor agonist)
IT 363-24-6, PGE2 59122-46-2, **Misoprostol** 60325-46-4, Sulprostone 69648-38-0, Butaprost
RL: PROC (Process)
(**prostaglandin** EP3 receptor binding of)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 1-7 (Pharmacology)
Section cross-reference(s): 4
TI Misoprostol protection against acetaminophen-induced hepatotoxicity in the rat
ST liver toxicity acetaminophen misoprostol
IT Liver
(misoprostol protection against acetaminophen-induced liver toxicity)
IT **Prostaglandins**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**misoprostol** protection against acetaminophen-induced liver toxicity)
IT 103-90-2, Acetaminophen
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(misoprostol protection against acetaminophen-induced liver toxicity)
IT 59122-46-2, Misoprostol
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(misoprostol protection against acetaminophen-induced liver toxicity)
IT 70-18-8, Glutathione, biological studies 27025-41-8, Oxidized glutathione

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(misoprostol protection against acetaminophen-induced liver toxicity)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-9 (Mammalian Hormones)
Section cross-reference(s): 15
TI Comparison of the prostaglandin E (EP) receptor of human neutrophils and HL-60 cells differentiated with DMSO
ST prostaglandin EP receptor neutrophil
IT Neutrophil
(prostaglandin EP receptor of human neutrophils and HL-60 cells differentiated with DMSO)
IT Prostaglandin receptors
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(EP2, prostaglandin EP receptor of human neutrophils and HL-60 cells differentiated with DMSO)
IT Animal cell line
(HL-60, prostaglandin EP receptor of human neutrophils and HL-60 cells differentiated with DMSO)
IT Receptors
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin EP2, prostaglandin EP receptor of human neutrophils and HL-60 cells differentiated with DMSO)
IT 67-68-5, DMSO, biological studies 363-24-6, PGE2 37786-00-8, 11-Deoxy-PGE1 41598-07-6, PGD2 59122-46-2, **Misoprostol** 60325-46-4, Sulprostone 60972-43-2, MB 28767 69552-46-1, Carbacyclin 69648-38-0, Butaprost 78919-13-8, Iloprost 94079-80-8, Cicaprost 148436-63-9, AH 13205
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**prostaglandin** EP receptor of human neutrophils and HL-60 cells differentiated with DMSO)
IT 60-92-4, CAMP
RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(prostaglandin EP receptor of human neutrophils and HL-60 cells differentiated with DMSO)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 1-7 (Pharmacology)
Section cross-reference(s): 2
TI the reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs can be reversed by prostaglandin E1 analog
ST glucocorticoid receptor synovium antiinflammatory; PGE1 glucocorticoid receptor synovium antiinflammatory
IT Chondrocyte
(prostaglandin E1 analog effect on reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)
IT Inflammation inhibitors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prostaglandin E1 analog effect on reduced expression of glucocorticoid

receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)
IT Corticosteroid receptors
Receptors
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(glucocorticosteroid, prostaglandin E1 analog effect on reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)
IT Arthritis
(osteoarthritis, prostaglandin E1 analog effect on reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)
IT Synovial membrane
(synoviocyte, prostaglandin E1 analog effect on reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)
IT 59122-46-2, **Misoprostol**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**prostaglandin** E1 analog effect on reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)
IT 745-65-3D, Prostaglandin E1, analog
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin E1 analog effect on reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)
IT 53-86-1, Indomethacin 22204-53-1, Naproxen 33005-95-7, Tiaprofenic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prostaglandin E1 analog effect on reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-0 (Mammalian Hormones)
TI The combined use of prostaglandin and antiprogestin in human fertility control
ST review prostaglandin antiprogestin fertility regulation; RU 486 PGE analog abortion review
IT Abortion
(prostaglandin combined with antiprogestin for fertility control in women)
IT Prostaglandins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prostaglandin combined with antiprogestin for fertility control in women)
IT Prostaglandins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E, prostaglandin combined with antiprogestin for fertility control in women)
IT Fertility
(female, prostaglandin combined with antiprogestin for fertility control in women)

IT 59122-46-2, **Misoprostol** 60325-46-4, Sulprostone 64318-79-2, Gemeprost 84371-65-3, RU 486
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**prostaglandin** combined with antiprogestin for fertility control in women)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-9 (Mammalian Hormones)
TI Effects of prostaglandin E1 analog, misoprostol, on the development of adjuvant arthritis in rats
ST misoprostol PGE analog arthritis antiulcer; antiinflammatory PGE analog arthritis
IT Ulcer inhibitors
(prostaglandin E1 analog misoprostol therapeutic effect on adjuvant arthritis development)
IT Inflammation inhibitors
(antiarthritics, prostaglandin E1 analog misoprostol therapeutic effect
on adjuvant arthritis development)
IT 745-65-3D, Prostaglandin E1, analogs 59122-46-2, **Misoprostol**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**prostaglandin** E1 analog misoprostol therapeutic effect on adjuvant arthritis development)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 14
TI The prostaglandin E1 analog, misoprostol, a normal tissue protector, does not protect four murine tumors in vivo from radiation injury
ST misoprostol radioprotection tumor radiotherapy
IT Gamma ray
Neoplasm
Radioprotectants
(prostaglandin E1 analog, misoprostol, normal tissue radioprotectant, does not protect murine tumors in vivo from radiation injury)
IT Radiotherapy
(gamma-ray, prostaglandin E1 analog, misoprostol, normal tissue radioprotectant, does not protect murine tumors in vivo from radiation injury)
IT 59122-46-2, **Misoprostol**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**prostaglandin** E1 analog, misoprostol, normal tissue radioprotectant, does not protect murine tumors in vivo from radiation injury)
IT 53-86-1, Indomethacin
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prostaglandin E1 analog, misoprostol, normal tissue radioprotectant, does not protect murine tumors in vivo from radiation injury along with
indomethacin)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-2 (Mammalian Hormones)
TI Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain
ST prostaglandin E receptor G protein coupling; structure activity prostaglandin receptor PGE2
IT Prostaglandin receptors

RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(EP3D, prostaglandin E receptor EP3D selective coupling to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain)

IT G proteins (guanine nucleotide-binding proteins)
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(Gi (adenylate cyclase-inhibiting), prostaglandin E receptor EP3D selective coupling to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain)

IT G proteins (guanine nucleotide-binding proteins)
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(Gs (adenylate cyclase-stimulating), prostaglandin E receptor EP3D selective coupling to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain)

IT Receptors
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(prostaglandin EP3D, prostaglandin E receptor EP3D selective coupling to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain)

IT Molecular structure-biological activity relationship
(receptor-binding, prostaglandin E receptor EP3D selective coupling to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and
arginine residue of seventh transmembrane domain)

IT 363-24-6, PGE2 59122-46-2, **Misoprostol** 60325-46-4, Sulprostone 60972-43-2, MB 28767 106342-69-2, GR 63799X 133906-74-8, TEI 3356
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(**prostaglandin** E receptor EP3D selective coupling to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain)

IT 74-79-3, L-Arginine, biological studies 9012-42-4, Adenylate cyclase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin E receptor EP3D selective coupling to Gi and Gs through interaction of .alpha.-carboxylic acid of agonist and arginine residue of seventh transmembrane domain)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-3 (Mammalian Hormones)
TI Use of **misoprostol** (**prostaglandin** E1 methyl analog) to expedite delivery in severe preeclampsia remote from term
ST misoprostol parturition preeclampsia
IT Parturition
Toxemia of pregnancy
(misoprostol to expedite delivery in severe preeclampsia remote from term)

IT 59122-46-2, Misoprostol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(misoprostol to expedite delivery in severe preeclampsia remote from term)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
IC ICM A61K031-557
CC 1-11 (Pharmacology)
TI Prostaglandin E derivatives in the treatment of dementia

ST prostaglandin deriv antiinflammatory agent dementia treatment; indomethacin prostaglandin E deriv dementia treatment

IT Brain
(microglial cell in tissue of; prostaglandin E derivs. in treatment of dementia)

IT Inflammation inhibitors
(prostaglandin E derivs. in treatment of dementia)

IT Corticosteroids, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prostaglandin E derivs. in treatment of dementia)

IT Prostaglandins
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E, prostaglandin E derivs. in treatment of dementia)

IT Mental disorder
(dementia, prostaglandin E derivs. in treatment of dementia)

IT 39391-18-9, Cyclooxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of; prostaglandin E derivs. in treatment of dementia)

IT 50-02-2, Dexamethasone 50-23-7, Cortisol 50-24-8, Prednisolone 53-03-2, Prednisone 53-06-5, Cortisone 83-43-2, Methylprednisolone 124-94-7, Triamcinolone 363-24-6, Prostaglandin e2 745-65-3, Prostaglandin e1 55028-70-1, Arbaprostil 59122-46-2, **Misoprostol** 69900-72-7, Trimoprostil 73121-56-9, Enprostil 77287-05-9, Rioprostil
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**prostaglandin** E derivs. in treatment of dementia)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS

IC ICM A61K031-557

CC 1-12 (Pharmacology)

TI Protective prostaglandins for use in conjunction with chemotherapeutic agents

ST chemotherapeutic tissue injury prostaglandin protection; cytotoxic agent tissue injury prostaglandin protection

IT Alopecia
Cytotoxic agents
Neoplasm inhibitors
(prostaglandins for protection against tissue injury from chemotherapeutics)

IT Prostaglandins
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prostaglandins for protection against tissue injury from chemotherapeutics)

IT Therapeutics
(chemo-, prostaglandins for protection against tissue injury from chemotherapeutics)

IT Animal tissue
(disease, injury, prostaglandins for protection against tissue injury from chemotherapeutics)

IT 50-07-7, Mitomycin C 50-18-0, Cytoxan 51-21-8, 5-Fluorouracil 59-05-2, Methotrexate 127-07-1, Hydroxyurea 147-94-4, Cytosine arabinoside 11056-06-7, Bleomycin 15663-27-1, Cisplatin 23214-92-8, Doxorubicin 33069-62-4, Taxol 33419-42-0, Etoposide 41575-94-4, Carboplatin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(prostaglandins for protection against tissue injury from chemotherapeutics)

IT 745-65-3, PGE1 39746-25-3, 16,16-Dimethyl prostaglandin E2
59122-46-2,
Misoprostol 138836-13-2, SC 44932
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(**prostaglandins** for protection against tissue injury from
chemotherapeutics)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-3 (Mammalian Hormones)
TI A comparison of 600 and 200 mg mifepristone prior to second trimester
abortion with the **prostaglandin misoprostol**
ST mifepristone second trimester abortion misoprostol; RU 486 abortion
prostaglandin
IT Abortion
(second trimester; ED of mifepristone administered prior to second
trimester abortion with **prostaglandin misoprostol**)
IT Parturition
(disorder, placenta retention, ED of mifepristone administered prior
to
second trimester abortion with **prostaglandin**
misoprostol)
IT 59122-46-2, Misoprostol 84371-65-3, Mifepristone
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(ED of mifepristone administered prior to second trimester abortion
with **prostaglandin misoprostol**)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 15-9 (Immunochemistry)
Section cross-reference(s): 2
TI Involvement of prostaglandins in the down-regulation of allergic plasma
leakage observed in rats undergoing pleural eosinophilia
ST prostaglandin allergic pleurisy eosinophilia
IT Mast cell
Signal transduction, biological
(prostaglandins in down-regulation of allergic plasma leakage in rats
with pleurisy eosinophilia)
IT Prostaglandins
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(prostaglandins in down-regulation of allergic plasma leakage in rats
with pleurisy eosinophilia)
IT Inflammation
(allergic, prostaglandins in down-regulation of allergic plasma
leakage
in rats with pleurisy eosinophilia)
IT Eosinophil
(disease, eosinophilia, prostaglandins in down-regulation of allergic
plasma leakage in rats with pleurisy eosinophilia)
IT Pleura
(disease, pleurisy, prostaglandins in down-regulation of allergic
plasma leakage in rats with pleurisy eosinophilia)
IT 59122-46-2, **Misoprostol** 61413-54-5, Rolipram 65154-06-5,
Blood platelet-activating factor
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(**prostaglandins** in down-regulation of allergic plasma leakage
in rats with pleurisy eosinophilia)
IT 60-92-4, CAMP 363-24-6, PGE2
RL: BAC (Biological activity or effector, except adverse); BPR
(Biological

process); BIOL (Biological study); PROC (Process)
(prostaglandins in down-regulation of allergic plasma leakage in rats with pleurisy eosinophilia)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-9 (Mammalian Hormones)
Section cross-reference(s): 15
TI Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation
and differentiation of mouse B lymphocytes to IgE-secreting cells
ST PGE 2 receptor B lymphocyte IgE
IT Lipopolysaccharides
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(prostaglandin E receptors of EP and EP subtypes regulation of responses mouse B lymphocytes to IL-4 and lipopolysaccharide)
IT Cell differentiation
Immunomodulators
(prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation
and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Lymphocyte
(B-cell, prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Immunoglobulins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(E, prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Prostaglandin receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(EP1, prostaglandin E2 receptors regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Prostaglandin receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(EP2, prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Prostaglandin receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(EP3.beta., prostaglandin E2 receptors regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Prostaglandin receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(EP4, prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Immunoglobulin receptors
Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(Fc.epsilon.RII (IgE fragment Fc receptor II), prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)
IT Histocompatibility antigens
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(MHC (major histocompatibility antigen complex), class II,

prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)

IT Lymphokines and Cytokines
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(interleukin 4, prostaglandin E2 receptors of EP2 and EP4 subtypes regulation of responses mouse B lymphocytes to IL-4 and lipopolysaccharide)

IT Receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(prostaglandin EP1, prostaglandin E2 receptors regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)

IT Receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(prostaglandin EP2, prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)

IT Receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(prostaglandin EP3.beta., prostaglandin E2 receptors regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)

IT Receptors
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(prostaglandin EP4, prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)

IT 363-24-6, Prostaglandin E2 59122-46-2, **Misoprostol**
69648-38-0, Butaprost
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**prostaglandin** E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)

IT 60-92-4, CAMP
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin E2 receptors of EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS

CC 2-9 (Mammalian Hormones)
Section cross-reference(s): 14

TI Effects of misoprostol and prostaglandin E2 on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants

ST misoprostol PGE2 proteoglycan articular cartilage loading; arthritis degeneration repair intraarticular prostaglandin

IT Arthritis
Stress, mechanical
(misoprostol and PGE2 effects on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants)

IT **Prostaglandins**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**misoprostol** and PGE2 effects on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants)

IT Proteoglycans, biological studies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(misoprostol and PGE2 effects on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants)
IT Cartilage
(articular, misoprostol and PGE2 effects on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants)
IT 363-24-6, PGE2 745-65-3, PGE1
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(misoprostol and PGE2 effects on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants)
IT 59122-46-2, Misoprostol
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(misoprostol and PGE2 effects on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 1-7 (Pharmacology)
TI Prevention of post-transplant peptic ulcer by misoprostol
ST misoprostol bismuth peptic ulcer kidney transplant; antacid ranitidine bismuth prostaglandin peptic ulcer
IT Peptic ulcer
Renal transplant
Transplant (organ)
(misoprostol for prevention of post-transplant peptic ulcer)
IT Antacids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(misoprostol for prevention of post-transplant peptic ulcer)
IT 7440-69-9, Bismuth, biological studies 59122-46-2, Misoprostol
66357-35-5, Ranitidine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(misoprostol for prevention of post-transplant peptic ulcer)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-2 (Mammalian Hormones)
TI Substitution of charged amino acid residues in transmembrane regions 6 and
7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor
ST prostaglandin EP3 receptor structure activity; signal transduction prostaglandin EP3 receptor
IT Ligand-binding structure-activity relationship
Receptor-binding structure-activity relationship
Signal transduction (biological)
Signal-transducing structure-activity relationship
(prostaglandin EP3 receptor charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction)
IT Gi proteins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin EP3 receptor charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction)
IT EP3 receptors
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(prostaglandin EP3 receptor charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal

transduction)
IT 60-92-4, CAMP
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin EP3 receptor charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction)
IT 363-24-6, PGE2 31753-17-0, PGE2 methyl ester 59122-46-2, **Misoprostol** 60325-46-4, Sulprostone 112137-89-0, Misoprostol-free acid
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(**prostaglandin** EP3 receptor charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction)
IT 74-79-3, Arginine, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin EP3 receptor residue 329; prostaglandin EP3 receptor charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction)
IT 56-84-8, Aspartic acid, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin EP3 receptor residue 338; prostaglandin EP3 receptor charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-9 (Mammalian Hormones)
TI Oral administration of misoprostol for labor induction: a randomized controlled trial
ST **misoprostol prostaglandin** labor pregnancy gastrointestinal tract
IT Gastrointestinal tract
Parturition
(oral administration of misoprostol for labor induction in humans)
IT Prostaglandins
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral administration of misoprostol for labor induction in humans)
IT 59122-46-2, Misoprostol
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(oral administration of misoprostol for labor induction in humans)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 2-3 (Mammalian Hormones)
TI A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction
ST misoprostol dinoprostone cervical ripening labor
IT Cervix (uterus)
Parturition
(comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction)
IT 363-24-6, Cervidil 59122-46-2, Cytotec
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS

CC 2-0 (Mammalian Hormones)
TI Antiulcer **prostaglandin misoprostol**: single and multiple dose pharmacokinetic profile
ST review misoprostol pharmacokinetics
IT 59122-46-2, Misoprostol
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmacokinetics of, in human)

L13 24 ANSWERS CAPLUS COPYRIGHT 2001 ACS
CC 29-9 (Organometallic and Organometalloidal Compounds)
Section cross-reference(s): 24, 26
TI In situ cuprate formation via transmetalation between vinylstannanes and higher order cyanocuprates
ST cuprate prepn transmetalation vinylstannane cyanocuprate; conjugate addn cycloalkenone cyanodiorganocuprate; **prostaglandin Misoprostol** analog synthesis transmetalation
IT Cycloalkenones
RL: RCT (Reactant)
(conjugate addn. reaction of, with cyanodiorganocuprates)
IT Addition reaction
(conjugate, of cycloalkenones and alkenones with cyanodiorganocuprates)
IT Metalation
(trans-, of vinylstannanes and cyanocuprates)
IT 112426-02-5
RL: PROC (Process)
(addn. of, to methyllithium)
IT 56745-67-6
RL: RCT (Reactant)
(conjugate addn. reaction of, with cyanodiorganocuprate, misoprostol analog from)
IT 112713-92-5
RL: RCT (Reactant)
(conjugate addn. reaction of, with cyanodiorganocuprates, misoprostol and analogs from)
IT 141-79-7, 4-Methyl-3-penten-2-one 22748-16-9, 4,4-Dimethyl-2-cyclopentenone
RL: RCT (Reactant)
(conjugate addn. reaction of, with diorganocyanocuprate)
IT 500-02-7, 4-Isopropyl-2-cyclohexenone 930-68-7, 2-Cyclohexenone
RL: RCT (Reactant)
(conjugate addn. reaction of, with diorganocyanocuprates)
IT 3884-92-2 82302-70-3
RL: RCT (Reactant)
(coupling of, to cyanodiorganocuprate enolate, misoprostol analog from)
IT 91328-63-1P 112713-99-2P 112714-00-8P 112714-02-0P
RL: RCT (Reactant); PREP (Preparation)
(formation and conjugate addn. reaction of, with cycloalkenone)
IT 112714-01-9P
RL: RCT (Reactant); PREP (Preparation)
(formation and conjugate addn. reaction of, with cycloalkenones)
IT 112714-04-2P
RL: RCT (Reactant); PREP (Preparation)
(formation and conjugate addn. reaction of, with cyclohexenone)
IT 78-59-1P, 3,5,5-Trimethyl-2-cyclohexenone
RL: RCT (Reactant); PREP (Preparation)
(formation and conjugate addn. reaction of, with methylpentenone)
IT 112714-03-1P
RL: RCT (Reactant); PREP (Preparation)

(formation and transmetalation of, with vinylstannane deriv.)
IT 1740-63-2P, 3-Vinylcyclohexanone 54125-16-5P 59122-46-2P
112713-85-6P 112713-86-7P 112713-87-8P 112713-88-9P 112713-89-0P
112713-90-3P 112713-93-6P 112713-94-7P 112713-97-0P 112713-98-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 112713-95-8 112713-96-9
RL: RCT (Reactant)
(transmetalation of, with cyanodimethylcuprate)
IT 112713-91-4
RL: RCT (Reactant)
(transmetalation of, with cyanodiorganocuprate)
IT 7486-35-3, Tributylvinylstannane 14275-61-7 91897-90-4 100073-20-9
112713-84-5
RL: RCT (Reactant)
(transmetalation of, with dimethylcyanocuprate)
IT 80473-70-7
RL: RCT (Reactant)
(transmetalation of, with vinylstannanes)
IT 69442-81-5
RL: RCT (Reactant)
(transmetalation with cyanodimethylcuprate and addn. of, to cyclopentenone deriv., misoprostol from)

ALL ANSWERS HAVE BEEN SCANNED

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	37.78	56.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.59

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:16:46 ON 11 MAY 2001
Connection closed by remote host